Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 30 May, 2024|Author: Getaka | Social: X Twitter Profile

Fundamental Analysis of Nectar Lifescience Ltd

About the Company - Nectar Lifescience Ltd

Nectar Lifesciences Ltd. is a Public Limited Listed company incorporated on 27/06/1995 and has its registered office in the State of Punjab, India. Company’s Corporate Identification Number(CIN) is L24232PB1995PLC016664 and registration number is 016664. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 1668.23 Cr. and Equity Capital is Rs. 22.43 Cr. for the Year ended 31/03/2022.
INDUSTRYADDRESSCONTACT
PharmaceuticalsVillage Saidpura, Tehsil Derabassi, Mohali Punjab 140507cs@neclife.com
http://www.neclife.com
Management
NamePosition Held
Mr. Sanjiv GoyalChairman & Managing Director
Dr. Indu Pal KaurIndependent Director
Mr. Ajay SwaroopIndependent Director
Dr. Rupinder TewariIndependent Director
Dr. Kuldip Kumar BhasinIndependent Director
Mr. Puneet SudWhole Time Director
Ms. Meena VermaNominee Director

Basic Stock Data of Nectar Lifescience Ltd

Last Updated: May 30, 2024, 6:19 am

Market Cap 748 Cr.
Current Price 33.4
High / Low45.7/16.5
Stock P/E150
Book Value 47.7
Dividend Yield0.00 %
ROCE5.98 %
ROE0.47 %
Face Value 1.00
PEG Ratio-6.25

Competitors of Nectar Lifescience Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
SMS Pharmaceuticals Ltd 1,738 Cr. 205219/82.441.8 60.70.15 %3.66 %0.84 % 1.00
Beta Drugs Ltd 1,300 Cr. 1,3521,595/66037.4 1480.00 %33.9 %28.6 % 10.0
TTK Healthcare Ltd 2,077 Cr. 1,4701,744/1,10133.0 7080.68 %8.67 %6.43 % 10.0
Adline Chem Lab Ltd 10.6 Cr. 18.129.0/6.55 2.920.00 %%% 10.0
Ambalal Sarabhai Enterprises Ltd 383 Cr. 50.070.0/20.967.4 17.90.00 %5.85 %4.24 % 10.0
Industry Average1,101.72 Cr619.0235.92187.500.17%10.42%8.02%8.20

Nectar Lifescience Ltd Quarterly Results

MonthDec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
Sales378.00348.78385.06364.57443.01476.24403.03388.65344.13388.81394.13397.97452.17
Expenses345.25319.55349.69337.11396.43427.09361.21396.05342.69370.72358.59371.11409.98
Operating Profit32.7529.2335.3727.4646.5849.1541.82-7.401.4418.0935.5426.8642.19
OPM %8.66%8.38%9.19%7.53%10.51%10.32%10.38%-1.90%0.42%4.65%9.02%6.75%9.33%
Other Income0.66-24.295.155.100.530.520.3610.7113.2417.920.4710.610.48
Interest30.6325.6525.7518.0117.6217.4321.3720.9917.4619.6617.6220.5224.84
Depreciation15.1015.0114.2814.1514.2814.2614.7014.7914.7814.8515.3315.3115.37
Profit before tax-12.32-35.720.490.4015.2117.986.11-32.47-17.561.503.061.642.46
Tax %34.50%-14.73%-265.31%-367.50%36.09%35.15%36.17%30.80%47.10%-144.67%40.52%38.41%36.18%
Net Profit-8.07-40.971.791.869.7311.663.90-22.47-9.293.681.821.021.57
EPS in Rs-0.36-1.830.080.080.430.520.17-1.00-0.410.160.080.050.07

Last Updated: April 10, 2024, 4:19 am

Nectar Lifescience Ltd Quarterly Chart

Nectar Lifescience Ltd Profit & Loss

Last Updated: May 28, 2024, 10:02 pm

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Sales1,3121,6221,6341,6381,6741,6351,8742,7792,3631,5411,6651,5201,633
Expenses1,0621,3321,3451,3711,4361,4111,6382,5142,1431,4321,5071,4671,510
Operating Profit25029028926723922423626422010915953123
OPM %19%18%18%16%14%14%13%10%9%7%10%3%8%
Other Income12161220623664-22114329
Interest115115138126123117115148126112797983
Depreciation61768477576264636160575961
Profit before tax8511578856467635937-8534-429
Tax %14%25%21%22%15%18%17%19%15%14%26%43%
Net Profit738662665455524832-7325-248
EPS in Rs3.263.822.772.952.422.472.332.121.42-3.271.12-1.080.36
Dividend Payout %3%3%4%3%4%2%2%2%4%0%0%0%

Nectar Lifescience Ltd Profit & Loss Yearly Chart

Nectar Lifescience Ltd Growth

Compounded Sales Growth
10 Years:0%
5 Years:-10%
3 Years:3%
TTM:11%
Compounded Profit Growth
10 Years:-22%
5 Years:-36%
3 Years:28%
TTM:108%
Stock Price CAGR
10 Years:2%
5 Years:11%
3 Years:0%
1 Year:93%
Return on Equity
10 Years:2%
5 Years:-1%
3 Years:-1%
Last Year:0%

Last Updated: May 25, 2024, 11:09 am

Nectar Lifescience Ltd Balance Sheet

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Sep 2023
Equity Capital22222222222222222222222222
Reserves7628459059369329841,0361,0831,1141,0401,0651,0421,045
Borrowings1,043879858925962878955903779903860754681
Other Liabilities293527609628640696710696718423443371394
Total Liabilities2,1212,2742,3942,5102,5562,5812,7242,7052,6332,3882,3912,1892,143
Fixed Assets858914948934906881852825785772723662826
CWIP150139122919910210010011599857878
Investments0001111101111
Other Assets1,1131,2211,3241,4851,5511,5971,7711,7801,7331,5171,5821,4491,239
Total Assets2,1212,2742,3942,5102,5562,5812,7242,7052,6332,3882,3912,1892,143

Nectar Lifescience Ltd Reserves and Borrowings Chart

Nectar Lifescience Ltd Cash Flow

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Cash from Operating Activity 165361255144169199652392852195134
Cash from Investing Activity -234-99-90-60-77-18-29-26-33-291752
Cash from Financing Activity 62-282-161-61-89-204-40-201-25211-119-186
Net Cash Flow-7-204233-23-412-04-8-0

Nectar Lifescience Ltd Financial Efficiency Indicators

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Debtor Days857984991071121197361899867
Inventory Days238216240253260270226151192185197212
Days Payable7812213914615416714280104108112100
Cash Conversion Cycle244172185207213215203145150166182179
Working Capital Days190137152173178186190129149190198204
ROCE %13%13%12%11%10%10%9%10%8%3%5%-0%

Nectar Lifescience Ltd Financial Efficiency Indicators Chart

Nectar Lifescience Ltd Share Holding Pattern

MonthDec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023
Promoters55.80%55.80%55.80%55.80%55.80%55.80%55.80%55.80%55.80%55.80%55.80%55.80%
FIIs2.62%2.62%2.62%2.46%1.52%1.67%1.49%16.12%15.99%16.07%16.00%16.02%
Government0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.02%0.02%0.02%0.02%0.02%
Public41.58%41.58%41.58%41.74%42.68%42.53%42.72%28.06%28.20%28.12%28.18%28.17%
No. of Shareholders46,73847,39453,30455,12456,07364,01263,90962,94064,42262,87461,58260,283

Nectar Lifescience Ltd Shareholding Pattern Chart

No. of Nectar Lifescience Ltd Shareholders

This stock is not held by any mutual fund

Nectar Lifescience Ltd ROCE Trend

Nectar Lifescience Ltd EPS Trend

Nectar Lifescience Ltd Key Financial Ratios

MonthMar 23Mar 22Mar 21Mar 20Mar 19
FaceValue1.001.001.001.001.00
Basic EPS (Rs.)-1.081.12-3.271.422.12
Diluted EPS (Rs.)-1.081.12-3.271.422.12
Cash EPS (Rs.)1.563.66-0.584.134.94
Book Value[Excl.RevalReserv]/Share (Rs.)47.4748.5147.3650.6649.28
Book Value[Incl.RevalReserv]/Share (Rs.)47.4748.5147.3650.6649.28
Revenue From Operations / Share (Rs.)67.9474.4268.82105.52124.09
PBDIT / Share (Rs.)4.297.575.039.9912.05
PBIT / Share (Rs.)1.655.032.347.289.23
PBT / Share (Rs.)-1.891.52-3.781.672.62
Net Profit / Share (Rs.)-1.081.12-3.271.422.12
NP After MI And SOA / Share (Rs.)-1.081.12-3.271.422.12
PBDIT Margin (%)6.3110.177.319.469.70
PBIT Margin (%)2.436.763.406.907.43
PBT Margin (%)-2.782.04-5.491.582.11
Net Profit Margin (%)-1.581.50-4.741.341.71
NP After MI And SOA Margin (%)-1.581.50-4.741.341.71
Return on Networth / Equity (%)-2.272.30-6.892.794.30
Return on Capital Employeed (%)2.858.134.0911.7814.72
Return On Assets (%)-1.101.04-2.961.201.75
Long Term Debt / Equity (X)0.210.260.120.100.14
Total Debt / Equity (X)0.700.790.790.650.72
Asset Turnover Ratio (%)0.660.680.600.881.03
Current Ratio (X)1.591.561.041.291.28
Quick Ratio (X)0.620.690.540.510.57
Inventory Turnover Ratio (X)1.391.651.131.942.51
Dividend Payout Ratio (NP) (%)0.000.00-1.533.522.83
Dividend Payout Ratio (CP) (%)0.000.00-8.611.211.21
Earning Retention Ratio (%)0.000.00101.5396.4897.17
Cash Earning Retention Ratio (%)0.000.00108.6198.7998.79
Interest Coverage Ratio (X)1.212.161.011.781.82
Interest Coverage Ratio (Post Tax) (X)0.691.320.571.251.32
Enterprise Value (Cr.)1091.931381.461231.83941.691163.72
EV / Net Operating Revenue (X)0.710.820.790.390.41
EV / EBITDA (X)11.358.1310.924.204.31
MarketCap / Net Operating Revenue (X)0.230.320.270.090.13
Retention Ratios (%)0.000.00101.5396.4797.16
Price / BV (X)0.330.490.390.190.34
Price / Net Operating Revenue (X)0.230.320.270.090.13
EarningsYield-0.060.04-0.170.140.12

Nectar Lifescience Ltd Profitability Ratios (%)

Nectar Lifescience Ltd Liquidity Ratios

Nectar Lifescience Ltd Liquidity Ratios (%)

Nectar Lifescience Ltd Interest Coverage Ratios (%)

Nectar Lifescience Ltd Valuation Ratios

Fair Value

Fair Value: ₹34.30

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

Undervalued: 2.70% compared to the current price ₹33.4

Intrinsic Value: ₹26.07

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators along with EPS growth.

Overvalued: 21.95% compared to the current price ₹33.4

Last 5 Year EPS CAGR: -24.00%

*Investments are subject to market risks

Strength and Weakness of Nectar Lifescience Ltd Stock

StrengthWeakness
  1. The company has higher reserves (983.77 cr) compared to borrowings (875.38 cr), indicating strong financial stability.
  2. The company has shown consistent growth in sales (1.15 cr) and profit (43.77 cr) over the years.
  1. The stock has a low average ROCE of 8.67%, which may not be favorable.
  2. The stock has a high average Working Capital Days of 173.00, which may not be favorable.
  3. The stock has a high average Cash Conversion Cycle of 188.42, which may not be favorable.

FAQ

What is the latest fair value of Nectar Lifescience Ltd?

The latest fair value of Nectar Lifescience Ltd is ₹34.30.

What is the Market Cap of Nectar Lifescience Ltd?

The Market Cap of Nectar Lifescience Ltd is 748 Cr..

What is the current Stock Price of Nectar Lifescience Ltd as on 30 May 2024?

The current stock price of Nectar Lifescience Ltd as on 30 May 2024 is ₹33.4.

What is the High / Low of Nectar Lifescience Ltd stocks in FY 2024?

In FY 2024, the High / Low of Nectar Lifescience Ltd stocks is 45.7/16.5.

What is the Stock P/E of Nectar Lifescience Ltd?

The Stock P/E of Nectar Lifescience Ltd is 150.

What is the Book Value of Nectar Lifescience Ltd?

The Book Value of Nectar Lifescience Ltd is 47.7.

What is the Dividend Yield of Nectar Lifescience Ltd?

The Dividend Yield of Nectar Lifescience Ltd is 0.00 %.

What is the ROCE of Nectar Lifescience Ltd?

The ROCE of Nectar Lifescience Ltd is 5.98 %.

What is the ROE of Nectar Lifescience Ltd?

The ROE of Nectar Lifescience Ltd is 0.47 %.

What is the Face Value of Nectar Lifescience Ltd?

The Face Value of Nectar Lifescience Ltd is 1.00.

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Nectar Lifescience Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE